How Oncotarget is Changing the Way Doctors See Cancer Treatment

Because Oncotarget is such a big publication and there are so many doctors who are working together to help each other with the treatment options they have, there are new ways the publication can feel good about what they are doing. They are confident there are different options they can use and that has helped them make sure things are going to get better. It has also allowed them the chance to experience a more positive outcome whiel they are helping other doctors connect with each other. For Oncotarget, this means they have to be able to continue growing. Once they are able to reach new levels of growth, they’ll be able to keep making things better for themselves. All of it comes down to how they can try different things and how they can make sure things are going to get better for them. It will allow them the chance to try more than what they have in the past. Check the journal at SCImago Journal & Country Rank.

By bringing attention to things like Oncotarget, Research Gate is making sure they are offering people a chance to see how things can get better. They want their clients to be able to trust what they have to offer and show other people what they can do to be successful. Thanks to Oncotarget, the changes that have happened in the industry have all been positive ones. Most people who are in the industry can see that difference and see how the publication is growing. Follow Oncotarget journal on Twitter.

The patients who are getting cancer treatment from doctors who are a part of Oncotarget are also confident they can make the right choices for the industry. As long as they are learning more and doing more, they will be able to try their best. They will also do what they can to help people realize there are different goals they can meet. Helping others is the easiest way for Oncotarget to keep growing and keep making a big difference. They want their doctors to have the best treatment options available so they can help all the patients they have worked with in their practices.

Follow: https://www.linkedin.com/company/oncotarget

Dr. Clay Siegall in a Personal Quest for Safer Cancer Therapies

Dr. Clay Siegall is motivated by a personal desire to find the cure for cancer. He watched his father suffer for seven years and eventually succumb to cancer. Watching his father’s suffering inspired him to find treatment for the disease. His priority was to attain relevant education. So he studied Zoology at Maryland University before attending George Washing University for a doctor of philosophy (Ph.D.) degree in Genetics. As a culmination of his interest, he founded Seattle Genetics. The company is developing into being the leading cancer research center in the world.

During an interview with Inspirey, Dr. Siegall said that his interest in finding an alternative cure for cancer intensified when as a student at Maryland University he observed the brutality of chemotherapy. The contemporary treatments then besides chemotherapy were amputations and radical therapy. Dr. Clay Siegall saw the need to find safer and less painful alternatives. After amassing sufficient experience in the field, he decided to create his company where he can manage the projects in such a way that met his intended purpose.

Seattle Genetics developed ADCetris, which became the first antibody drug conjugate, ADC, to be approved by the FDA. It has earned the company a lot of revenue. Clay Siegall believes the drug will enjoy its monopoly status for a few more years. It takes a lot of financial risks investing in drug production; in fact, the company took ten years after the Initial Public Offer to become profitable. Therefore the research center has created other sources of revenue through production partnerships and licensing of the process and technologies they have developed.

Quality, marketing, negotiating and passion are four strategies that best explains the success of Seattle Genetics. Dr. Siegall explains that their products’ quality and uniqueness helps it, to a large extent, to sell itself. Nevertheless, the company still employs the most talented salespersons with a background in biotechnology and an extensive knowledge of the product. He points out that closing any luxurious deals requires a lot of negotiating and meetings. Passion is his driving force. It motivates him to focus and work towards his goal; finding effective alternative cancer therapies.